Literature DB >> 30972908

Branched chain amino acids are associated with the heterogeneity of the area of lipid droplets in hepatocytes of patients with non-alcoholic fatty liver disease.

Eiji Kakazu1, Akitoshi Sano1, Tatsuki Morosawa2, Jun Inoue1, Masashi Ninomiya1, Tomoaki Iwata1, Takuya Nakamura1, Satoshi Takai1, Shojiro Sawada3, Hideki Katagiri3, Tooru Shimosegawa1, Atsushi Masamune1.   

Abstract

AIM: Macrovesicular steatosis around the central vein (zone 3) is one of the pathological features of non-alcoholic fatty liver disease or steatohepatitis (NAFLD/NASH). The aim of this study is to elucidate precisely the association between the area of lipid droplets (LDs) and the plasma metabolic parameters in patients with NAFLD/NASH.
METHODS: Eighty patients with NAFLD/NASH diagnosed by needle biopsy were enrolled. The LDs around zone 3 were counted automatically by image processing software, the total area of LDs (TLDs), the maximum area of LDs (MAXLDs), the average area of LDs (AVELDs) and the heterogeneity by the coefficient of variation (CV [%]) were quantified. The correlations between these values and plasma metabolic parameters were analyzed. We evaluated the association between branched chain amino acids (BCAAs) and the heterogeneity of LDs in hepatocytes in vitro and in vivo.
RESULTS: The MAXLDs was significantly correlated with more metabolic parameters than AVELDs and TLDs. The level of BCAAs was independently associated with the CV among the metabolic parameters. In early stage NAFLD, aspartate and alanine aminotransferase were significantly higher in the high CV group than in the low CV group. The high concentration of BCAAs increased the CV of LDs in hepatocytes accompanied by the expression of phosphor-p70 S6 kinase and sterol regulatory element-binding protein 1 in vitro. A high BCAA diet induced high heterogeneity of LDs around zone 3 in ob/ob mice.
CONCLUSIONS: The levels of BCAAs were associated with the LD heterogeneity of hepatocytes around zone 3 in patients with NAFLD/NASH.
© 2019 The Japan Society of Hepatology.

Entities:  

Keywords:  BCAA; NAFLD; NASH; lipid droplet; steatosis

Year:  2019        PMID: 30972908     DOI: 10.1111/hepr.13346

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  4 in total

1.  Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study.

Authors:  M Angeles Zulet; Itziar Abete; Cristina Galarregui; Irene Cantero; Bertha Araceli Marin-Alejandre; J Ignacio Monreal; Mariana Elorz; Alberto Benito-Boillos; José Ignacio Herrero; Víctor de la O; Miguel Ruiz-Canela; Helen Hermana M Hermsdorff; Josefina Bressan; Josep A Tur; J Alfredo Martínez
Journal:  Eur J Nutr       Date:  2020-08-28       Impact factor: 5.614

Review 2.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.

Authors:  Mojgan Masoodi; Amalia Gastaldelli; Tuulia Hyötyläinen; Enara Arretxe; Cristina Alonso; Melania Gaggini; Julia Brosnan; Quentin M Anstee; Oscar Millet; Pablo Ortiz; Jose M Mato; Jean-Francois Dufour; Matej Orešič
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-10       Impact factor: 46.802

3.  Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis.

Authors:  Moongi Ji; Yunju Jo; Seung Joon Choi; Seong Min Kim; Kyoung Kon Kim; Byung-Chul Oh; Dongryeol Ryu; Man-Jeong Paik; Dae Ho Lee
Journal:  Biomedicines       Date:  2022-07-11

4.  Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study.

Authors:  Keisuke Nakanishi; Tadashi Namisaki; Tsuyoshi Mashitani; Kosuke Kaji; Kuniaki Ozaki; Soichiro Saikawa; Shinya Sato; Takashi Inoue; Yasuhiko Sawada; Kou Kitagawa; Hiroaki Takaya; Naotaka Shimozato; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  Nutrients       Date:  2019-09-07       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.